Dr Reddy's Laboratories to stay focussed on emerging markets for growth

Today, combined revenue from emerging markets and India finely balance that of the North America, at 38%of the total

Dr Reddy’s Laboratories (DRL) says it would keep focusing on emerging markets (which includes Russia and the CIS countries) and India for business growth, organically and via acquisitions.
 
The idea, it says, is to minimise dependence on any single region. Its growth was affected in the aftermath of a warning letter in 2015 from the American sector regulator, the Food and Drug Administration (FDA). At the time, US revenues were half its global sales of generic medicines and largely drove Dr Reddy’s generics formulation business. Today, combined revenue from emerging markets and India finely balance that of the North